European Molecular Biology Laboratory (Heidelberg) Featured PhD Programmes
University of Portsmouth Featured PhD Programmes
Engineering and Physical Sciences Research Council Featured PhD Programmes
Birkbeck, University of London Featured PhD Programmes
Kingston University Featured PhD Programmes
"january"×
10 miles

Cancer / Oncology (january) PhD Projects, Programs & Scholarships

We have 51 Cancer / Oncology (january) PhD Projects, Programs & Scholarships

  • "january" ×
  • Cancer / Oncology×
  • clear all
Order by 
Showing 1 to 30 of 51
  Regulation of apoptosis-induced compensatory cell proliferation and its implications for cancer and tissue regeneration
  Dr Y Fan
Applications accepted all year round

Funding Type

PhD Type

In multi-cellular organisms, coordinated cell death (e.g. apoptosis) and cell replacement is critical for tissue recovery in response to stress or damage.
  Fully-funded PhD positions in several natural sciences & engineering disciplines

Funding Type

PhD Type

Join an internationally renowned scientific community with the Hector FellowPhD program. PhD students benefit not only from the experience of the program, but also from the network of Hector Fellows.
  Investigate a novel, unexplored link between WNT signalling and regulators of cell migration in cancer progression using CRISPR-Cas9 and advanced live cell imaging.
  Dr M Krause
Applications accepted all year round

Funding Type

PhD Type

Cancer is a devastating disease. more than one in three people in the UK will develop cancer in their lifetime. WNT signalling is a key pathway controlling morphogenesis in embryos and it has been shown that perturbations of this pathway promote cancer progression.
  CONTRAsT - Cisplatin analogue gOld Nanoparticles for Tumour RAdiation Therapy
  Dr J Coulter
Application Deadline: 29 February 2020

Funding Type

PhD Type

This three year PhD position is an exciting industrial/academic collaboration which will afford the appointed student the opportunity to work closely with our partners Midatech Pharma.
  Dissecting novel mechanisms of cysteine protease biology in tumourigenesis
  Dr R Burden, Prof C Scott
Applications accepted all year round

Funding Type

PhD Type

Proteases are known for their role in facilitating tumour development, primarily through processes such as proliferation and invasion.
  Long-acting drug delivery from intravaginal rings for treatment of cervical intraepithelial neoplasia
  Prof K Malcolm, Dr P Boyd
Applications accepted all year round

Funding Type

PhD Type

Building on our world-renowned expertise in vaginal drug delivery, the aim of this project is to develop a long-acting vaginal ring device for treatment of cervical intraepithelial neoplasia.
  Nano-engineered Delivery Systems for the Targeted Delivery of Oncology Drugs for Non-Small Cell Lung Cancer
  Dr H McCarthy, Dr N Buckley
Applications accepted all year round

Funding Type

PhD Type

Lung cancer is the most common cancer worldwide accounting for 11.6% of the global burden. The standard of care (SoC) chemotherapy typically involves a ‘cocktail’ of drugs which confer debilitating side-effects, resulting in sub-optimal dosing with a reduced clinical efficacy.
  Peptide hydrogels as novel nanotherapeutic delivery agents enhancing the anti-tumour efficacy of radiotherapy
  Dr J Coulter, Dr G Laverty
Applications accepted all year round

Funding Type

PhD Type

There is a pressing clinical need for effective localised cancer treatments. Addressing this need we will develop a novel drug delivery system comprised of a nanoparticle/drug releasing hydrogel implant.
  Personalised Medicine for Breast and Ovarian Cancer
  Dr N Buckley, Dr H McCarthy
Applications accepted all year round

Funding Type

PhD Type

One in two people will develop cancer in their lifetime and it is a leading cause of death. While significant progress has been made in the treatment of some cancers, there still remain some forms of the disease with limited treatment options and poor outcome.
  To develop an allosteric inhibitor of HDAC6 inhibition in cancer
  Dr F Furlong, Dr I Tikhonova
Applications accepted all year round

Funding Type

PhD Type

The HDAC6 protein is upregulated in cancer and associated with increased proliferation and metastasis. Several HDAC6 inhibitors have been developed and are in clinical trials.
  USP17 as a cancer therapeutic target
  Dr J Burrows
Applications accepted all year round

Funding Type

PhD Type

USP17 is over-expressed in a range of primary tumours including NSCLC, breast, colorectal, cervical, ovarian and osteosarcoma and its depletion has been shown to block the growth of cells from all these cancer types.
  Autoimmunity against TNF and its role in inflammatory diseases
  Dr S Jiang, Dr N Burgess-Brown
Application Deadline: 3 March 2020

Funding Type

PhD Type

THE PROJECT. Tumour Necrosis Factor (TNF) is a pro-inflammatory cytokine. It regulates a complex signalling network able to trigger cell survival, as well as cell death via apoptosis or necrosis/necroptosis.
  Bispecific monoclonal antibodies for cancer immunotherapy
  Prof W Bodmer, Prof P McHugh
Application Deadline: 3 March 2020

Funding Type

PhD Type

THE PROJECT. Monoclonal antibodies (MCAs) are now widely used for cancer therapy. DNA recombinant technology enables the production of MCAs that target cancer specific determinants and immune cells, attracting them to the cancer cells and so killing them.
  Characterisation of DNA-protein crosslink proteolysis repair in cancer and therapy
  Prof K Ramadan, Prof B Kessler
Application Deadline: 3 March 2020

Funding Type

PhD Type

THE PROJECT. DNA-protein crosslinks (DPCs) are under-investigated DNA lesions caused by the covalent attachment of proteins to DNA.
  Combining CRISPR and RNAseq to dissect molecular circuits in a hypoxic tumour microenvironment
  Prof F Buffa, Prof A Harris, Dr V D'Angiolella
Application Deadline: 3 March 2020

Funding Type

PhD Type

THE PROJECT. The role of the microenvironment in driving tumour progression is increasingly recognized. Hypoxia is one of the key microenvironmental changes between tumour and normal tissue, and adaptation of cancer cells to this hostile environment contributes to their malignancy and aggressive phenotype.
  Cross presentation of antigens of recombinant overlapping peptides to optimise vaccines against tumour and infectious diseases
  Dr S Jiang, Dr N Burgess-Brown
Application Deadline: 3 March 2020

Funding Type

PhD Type

THE PROJECT. We have developed a technology to producing overlapping peptides - bacterial expression of an amino acid sequence corresponding to overlapping peptide sequences spanning the length of a protein of interest interspersed with enzymatic cleavage sites.
  Differentiation in colorectal cancer
  Prof W Bodmer, Prof P McHugh
Application Deadline: 3 March 2020

Funding Type

PhD Type

THE PROJECT. Derangement of cellular differentiation is a key step in adenocarcinoma progression. Understanding this should provide novel targets for the development of new treatments, and new approaches to diagnosis and early detection.
  DNA repair fidelity, radiosensitivity and cancer.
  Prof T Humphrey, Dr V D'Angiolella
Application Deadline: 3 March 2020

Funding Type

PhD Type

THE PROJECT. With almost half of all cancer patients receiving radiotherapy, tumour-specific radiosensitization remains an important goal for cancer research.
  Early detection of oesophageal cancer
  Prof K Vallis, Prof B Vojnovic
Application Deadline: 3 March 2020

Funding Type

PhD Type

THE PROJECT. Oesophageal cancer is an area of unmet clinical need; late diagnosis is one of the reasons that cure rates remain stubbornly low.
  Exosomes in oncolytic virotherapy
  Prof L Seymour, Dr K Fisher
Application Deadline: 3 March 2020

Funding Type

PhD Type

THE PROJECT. Oncolytic viruses promise new opportunities for targeted cancer therapy, but spread of viruses through solid tumour masses is often limited.
  Hypoxia links the unfolded proteim response with the DNA damage response
  Prof E Hammond, Prof A Giaccia
Application Deadline: 3 March 2020

Funding Type

PhD Type

THE PROJECT. Regions of hypoxia (insufficient oxygen) occur in most if not all solid tumours and are clinically relevant as they correlate with poor patient prognosis and therapy resistance.
  Inflammation in the tumour microenvironment
  Dr E Parkes, Dr J Rehwinkel
Application Deadline: 3 March 2020

Funding Type

PhD Type

THE PROJECT. A key part of tackling cancer is understanding the tumour microenvironment, in particular the immune microenvironment.
  Investigating how cells repair DNA damage during mitosis
  Dr A Blackford, Dr D Clynes
Application Deadline: 3 March 2020

Funding Type

PhD Type

DNA damage poses a serious threat to proper chromosome segregation during cell division, and if repaired incorrectly can cause cell death or cancer.
  Investigating IGF-1 as a cancer risk factor
  Prof V Macaulay, Prof C Verrill
Application Deadline: 3 March 2020

Funding Type

PhD Type

THE PROJECT. The focus of this research project is the investigation of insulin-like growth factors (IGFs) as risk factors for development of cancer.
  Investigation of the contribution of redox stress to the therapy resistance of cells experiencing cycling oxygen levels
  Prof E Hammond, Dr S Conway
Application Deadline: 3 March 2020

Funding Type

PhD Type

THE PROJECT. Hypoxia is a major barrier to successful cancer treatment as the more hypoxic a tumour, the less well patients respond.
  MROnics used in MR Linac applications
  Prof F Van den Heuvel, Dr S Vinko
Application Deadline: 3 March 2020

Funding Type

PhD Type

HE PROJECT. The advent of clinically implemented MR Linacs generates an excess of available imaging data. This can be leveraged to predict the outcome of the treatment and provide valuable information in a biological adaptation of a patients’ treatment.
  Pre-clinical investigations of POLQ inhibitors
  Dr G Higgins, Prof T Humphrey
Application Deadline: 3 March 2020

Funding Type

PhD Type

THE PROJECT. The aim of our research is to improve radiotherapy for cancer patients by making tumour cells more sensitive to radiation without affecting the sensitivity of normal cells.
  Strategies to enhance efficacy of nucleotide therapeutics for targeted cancer therapy
  Prof K Vallis, Prof T Brown
Application Deadline: 3 March 2020

Funding Type

PhD Type

THE PROJECT. Oligonucleotide (ON) drugs hold promise in cancer medicine as they offer exquisitely precise inhibition of DNA and RNA targets.
  Targeting DNA repair to overcome cancer therapy resistance
  Prof P McHugh, Prof T Brown
Application Deadline: 3 March 2020

Funding Type

PhD Type

THE PROJECT. DNA cross-linking drugs and radiotherapy (RT) are used to treat a range of tumours including many hard-to-treat cancers (e.g.
  Targeting telomere maintenance and repair in cancer.
  Dr D Clynes, Dr A Blackford
Application Deadline: 3 March 2020

Funding Type

PhD Type

THE PROJECT. Cancer occurs through the uncontrolled division of cells. The number of times a cell can divide is limited by the length of specialised DNA sequences found at the end of chromosomes called telomeres.
Show 10 15 30 per page


FindAPhD. Copyright 2005-2020
All rights reserved.